Neumora Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Neumora Therapeutics Inc in the second quarter 2026?
Neumora Therapeutics Inc recorded a cumulative net loss of $-213 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -242.28%.

Within the Biotechnology & Pharmaceuticals industry 98 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3569 to 3645.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-75.66 %	-69.05 %	-63.82 %	-58.79 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-213	-222	-237	-236	-252
Return On Equity (TTM)	-242.28 %	-181.7 %	-146.42 %	-113.81 %	-98.95 %
NMRA's Total Ranking	# 3645	# 3569	# 3200	# 3252	# 3003
Equity (TTM) in Millions	45	71	104	132	183
Seq. Equity Change	-37.01 %	-31.95 %	-21.41 %	-27.73 %	-19.92 %
Seq. Net Income Change	-	-	-	-	-

Back to NMRA Management Effectiveness >> NMRA's 5 Years Annual ROE >> Compare NMRA ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 99
Sector	# 686
Overall	# 3645

Return On Equity Statistics
High	Average	Low
-25.16 %	-110.57 %	-242.28 %
(Jun 30 2024)		(Jun 30 2026)

News about Neumora Therapeutics Inc Return on Equity ROE

Neumora Therapeutics Announces Leadership Transition Amid Financial Challenges and Legal Pressures

Neumora Therapeutics Inc. a biopharmaceutical company focused on transforming the treatment landscape for neurological diseases, has recently garnered attention following a significant leadership transition. Paul L. Berns, currently serving as executive chair of the Neumora Board of Directors, will step into the role of chief executive officer (CEO) and chairman of the Board. This transition comes at a critical time for the company, as it navigates through various financial hurdles and legal matters.Leadership Changes and Future DirectionThe appointment of Berns as CEO is expected to bring a new strategic approach to Neumora. With an extensive background in the biotech industry, Berns has held leadership positions in various pharmaceutical companies, providing him with the experience necessary to guide Neumora through its current challenges. His vision for the company and its long-term objectives will be under scrutiny as investors look for signs of turnaround and stability.

NMRA Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023
Total Equity in Millions	104	287	469	0	0
Y / Y Equity Change	-63.82 %	-38.8 %	-	-	-
Net Income in Millions	-237	-244	-236	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-228.1 %	-84.92 %	-50.3 %	-	-

Back to NMRA Management Effectiveness >> NMRA's 5 Years Annual ROE >> Compare NMRA ROE to its Competitors

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NMRA's' Return on Equity at Yahoo Finance
NMRA's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NMRA's Competitors
Subscribers only: Roe for Neumora Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for NMRA's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-26T07:42:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.